A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

What Was Tested

The paper reports a study of Octreotide, published as a randomized controlled trial.

Who Took Part

The abstract describes 172 adults taking part.

PubMed indexes the participants as adults, both men and women.

A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.

The mean age (38 +/- 11 year), weight (110.7 +/- 23 kg), and BMI (39.8 +/- 6.5 kg/m2) were similar across the four treatment groups.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the adults and researchers unaware of who received Octreotide.

Some adults received a placebo instead of Octreotide, giving a reference point.

Safety measures included medical history, vital signs, physical examinations, hematology, blood chemistries, thyroid function tests, hemoglobin A1c, gallbladder ultrasound, electrocardiograms, and adverse events.

What Was Measured

The subject headings attached to it are Black or African American, Analysis of Variance, Anti-Obesity Agents, Asian People, Chi-Square Distribution, Insulin and Insulin Secretion.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide in 172 adults.

The abstract goes on to report its results in about 13 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (International journal of obesity (2005)), a journal based in England.

More context: the Octreotide compound page, all human trials.